

2nd annual



**NORDIC
CONGRESS**

28-29 August, 2019
Nasdaq Offices
Stockholm
Sweden



STRATEGY, INVESTMENT AND PARTNERING FOR LIFE SCIENCE EXECUTIVE LEADERS

www.lsxleaders.com/lxx-nordic-congress

Created by:



The network
for life science
executive leaders



CONNECT WITH PURPOSE

The LSX Nordic Congress is a high-calibre, senior executive conference and partnering event providing the education, strategies, solutions, and contacts that life science companies need to enable more effective investment, business planning and partnering within their businesses.

The Nordic region has long produced world-leading science and innovation and, now in its second year, the LSX Nordic Congress will be all about showcasing this innovation, both of the region's industry leaders but also through start-ups and technology innovators driving the future of healthcare.


Nasdaq Nordic is one of the leading hubs for life sciences in Europe, strengthened further by an active IPO market in the last few years, and we're delighted to be working again with Nasdaq as hosts of the congress. But this is not just for listed companies. This is the executive strategy, investment and partnering event for companies of all sizes, addressing challenges in their ongoing funding, growth, development and internationalisation.

With our growing international community of investors and pharma, our aim and mission is to bring investors to the Nordic region and connect Nordic executives with capital and partners, as well as peer-to-peer knowledge exchange.

Join us in Stockholm!






6 REASONS TO ATTEND...

- 1 UNDERSTAND...** the latest trends, forecasts and insights from leading regional investment funds and Nordic life science leaders
- 2 HEAR...** war stories, advice and key success factors from CEOs who have taken their company through major milestones and who are internationalising their businesses
- 3 PARTICIPATE...** in one of our unique, curated, invitation-only Chatham House Rule CEO Forums - Public, Private and for Health Tech Innovators
- 4 NETWORK...** with 200 Nordic life science CxOs, international investors and key partners, convening to address key executive issues facing companies in the region
- 5 PRESENT...** your company to an audience of qualified investors in person, as well as being recorded and promoted afterwards in our Inv€\$table showcase sessions
- 6 CONNECT WITH PURPOSE...** to our community - the life science executives of LSX.



AGENDA AT A GLANCE

WEDNESDAY AUGUST 28

9.00			
12.00	 <p>Early stage innovation, fundraising and partnering in the Nordic region</p>	 <p>Exclusively for publicly listed Nordic life sciences companies</p>	 <p>Exclusively for 8 pre-IPO companies and bootcamp partners</p>
14.30	 <p>Startup Showcase</p> <p>10 x 10 minute company showcases for startups 6 x 15 minute showcases for growth stage private companies</p>		
18.00	<p>Networking Drinks and 1-2-1 Partnering</p>	 <p>Exclusively for Public CEO Forum participants</p>	
21.00			

THURSDAY AUGUST 29

9.00	 <p>Opening Plenary: Internationalisation and building the Nordic ecosystem</p>		
11.00	 <p>Private Growth Company Showcase 6 x 15 minutes company showcases for growth stage Nordic life science companies</p>	 <p>Exclusively for CxOs HealthTech companies</p>	1 2 1 P A R T N E R I N G
13.30	 <p>Public Company Showcase 12 x 15 minutes company showcases for publicly listed Nordic life science companies</p>	 <p>Exclusively for growth stage private Nordic life sciences companies</p>	
17.00	<p>Closing Plenary: Public markets and the Nordics in a Global Context</p>		

AGENDA DAY 1 - WEDNESDAY AUGUST 28

12:00

ARRIVAL & REGISTRATION

12:30

LSX WELCOME ADDRESS

Matthew Pullan, SVP BD, LSX

12.35

OPENING PANEL: MATCHING RECORD EARLY AND GROWTH STAGE INVESTMENT IN THE NORDICS

Executives of leading investment firms discuss and debate the current seed and growth investment landscape in the region, strategies for nurturing the ecosystem and strategies for building the next wave of Nordic life science leaders.

- Can and will we see a stronger backing and risk appetite in the Nordics with larger seed and growth deals, as is being seen across the rest of Europe?
- What advice would you give innovation projects looking for early stage funding?
- For growth stage companies, how do you feel they can best position themselves for investment?
- The route public - if and when should companies consider this route with such robust public markets in the Nordics?

Ekaterina Gianelli, Partner, Inventure (moderator)
Søren Møller, Managing Partner, Novo Seeds
Roger Franklin, Partner, Hadean Ventures
Andreas Jurgeit, Partner, Lundbeckfonden Emerge
Farzad Abdi-Dezfuli, Partner - Investment Advisor, Sarsia Seed
Andreas Lindblom, CEO, Sciety
Patrik Sobocki, Investment Manager, Industrifonden

13.25

PHARMA COLLABORATION, INVESTMENT & PARTNERING IN THE NORDICS

Regional and international pharma executives discuss the evolving role of pharma and support for life science innovators, as well as how companies can most effectively position themselves and connect with the right pharma partners.

- How do local international pharma view the Nordic region in a global context? What sort of initiatives and support are available to help develop the Nordic life science ecosystem?
- Is it becoming more or less common for equity positions to be taken in potential early stage partners alongside a license or collaboration deal?
- How are the partnering and collaboration strategies evolving?
- Which areas of innovation are pharma focussed on? How do partnerships differ across biotech, medtech and healthtech?

Thomas Lönngren, Former Head of the EMA and Strategic Advisor, NDA Group (moderator)
Miriam Freiden, VP Search & Evaluation, Novo Nordisk
Magnus Björnsne, CEO, AstraZeneca BioVenture Hub
Michel de Baar, Executive Director BD&L, MSD
Jørund Sollid, Head of BD&L Nordic Region, Mundipharma



Co-host partners:



Nordic Capital Markets Outlook:

Adam Kostyal, SVP, Head of European Listings
Nasdaq
Peter Legind-Hansen, Managing Director, Nasdaq

Legal Trends Case Study:
Erik Sjöman, Partner, Vinge
Dain Hård Nevenon, Partner, Vinge

M&A and Deal Landscape:
Magnus Lagerberg, Partner, PwC
Johan Engstam, Partner, PwC

14.05

NETWORKING BREAK

14.35

14.35 Jesper Roested, CEO, Subcuject



STARTUP SHOWCASE



14.45 Martin Olovsson, CEO, OnDosis



14.55 Trude Tingvoll, CEO, Respinor





15.05 Simon Fredriksson, CEO, Genagon Therapeutics



Building a company and shareholder value in a Nordic giant:

Guido Oelkers, CEO, Sobi

AGENDA DAY 1 - WEDNESDAY AUGUST 28

	<p style="text-align: center;"> STARTUP SHOWCASE</p> <p>15.15 Casper Slots, CCO, Particle3D </p> <p>15.25 Espen Riskedal, CEO, Age Labs </p> <p>15.35 Michael Åkesson, Chair of the Board, MEDVasc </p> <p>15.45 Cecilia Belfrage, CEO, Umansense </p> <p>15.55 Cristiana Pires, CEO, Asgard Therapeutics </p> <p>16.05 Erik Rask, CEO, MedBeat </p>	<p style="text-align: center;"></p> <p>Building international big biotech:</p> <p>Don Debethizy, Chair, Saniona & Director, Argenx</p>
<p>16.15</p>	<p style="text-align: center;"> PRIVATE GROWTH SHOWCASE</p> <p>16.15 Torben Skarsfeldt, COO, Serodus </p> <p>16.30 Nicolas Elvemo, CEO, GlucoSet </p> <p>16.45 Reagan Jarvis, CEO, Anocca </p> <p>17.00 Michael Malkoch, CEO, Biomedical Bonding </p> <p>17.15 Ulf Sewerin, CEO, AddBIO </p> <p>17.30 Mikko Savola, CEO, Monidor </p> <p>17.45 Sofia Mayans, CEO, InfiCure Bio </p>	<p>Aquisition case study:</p> <p>Alex Haahr Gouliaev, CEO, Nuevolution</p>
<p>18.00</p>	<p>NETWORKING DRINKS RECEPTION</p>	

AGENDA DAY 2 - THURSDAY AUGUST 29

08:00	ARRIVAL & REGISTRATION
09:00	LSX WELCOME ADDRESS Josh Dance, SVP, LSX
09.05	NASDAQ WELCOME ADDRESS Adam Kostyal, SVP Listing Services – Europe, Nasdaq
09.10	GROWTH AND DEVELOPMENT IN THE SWEDISH LIFE SCIENCES LANDSCAPE Carl Wadell, Analyst, Swedish Agency for Growth Policy Analysis
09.20	BUILDING AND INTERNATIONALISING THE NORDIC LIFE SCIENCES ECOSYSTEM Key stakeholders from across the region debate and discuss strategies for growth, development and internationalisation of the life sciences sector and the evolution of a robust ecosystem of leading Nordic companies to address global healthcare challenges. <ul style="list-style-type: none"> • How can companies, investors, and the wider industry try to collaborate better and address fragmentation of the Nordic ecosystem? • Developing and cultivating a dominant ecosystem to encourage further investment • How are newly released life sciences strategies of regional Governments being implemented? <p>Adam Kostyal, SVP Listing Services – Europe, Nasdaq (moderator) Guido Oelkers, CEO, Sobi Renee Aguiar-Lucander, CEO, Calliditas Therapeutics Rasmus Beedholm Ebsen, Special Advisor - Life Sciences, Ministry of Foreign Affairs, Denmark</p>
10.00	BUILDING INTERNATIONAL LIFE SCIENCES LEADERS THROUGH SYNDICATION Regional and international investors discuss the challenges and opportunities for collaboration and syndication to build the next wave of Nordic companies as well as how companies can best position themselves and develop in an ever-competitive global market. <ul style="list-style-type: none"> • Reaching international specialist funding: syndication and developing networks to access European and US growth capital • Could we see more PIPE (private investment in public equity) deals to support growing public companies? • Biotech, medtech, healthtech – where can we expect the next wave of innovation and growth? • Could the ongoing success in successful listings and successful fundraises attract more growth capital investment to the region? <p>Ingrid Akay, Managing Partner, Hadean Ventures (moderator) Henriette Richter, Managing Partner, Sofinnova Partners Mårten Steen, Partner, HealthCap Søren Lemonius, General Partner, Sunstone Capital David Germonpré, Investment Partner, MTIP Jonas Jendi, Investment Manager, Industrifonden</p>

10.40 NETWORKING BREAK

11.00		PRIVATE GROWTH SHOWCASE	
	11.00 Jonas Tyssø, COO, Cardiacss		<p>Moderated by: Lucy Robertshaw, Director, LucyJRobertshaw</p> <p>Fundraising case study: Martin Lindman, CEO, Doktor.se</p>
	11.15 Kjell Are Furnes, CEO, ABLY		
	11.30 Michael Rützler, CEO, ApoGlyX		
	11.45 Lao Saal, CEO, SAGA Diagnostics		
	12.00 Alan Knox, CEO, Primex Pharmaceuticals		
	12.15 Visa Sippola, CEO, Surgify Medical		

12.30 NETWORKING LUNCH

13.30



PUBLIC
SHOWCASE

13.30 Magnus Corfitzen, CEO, Ascelia Pharma



13.45 Martin Åmark, CEO for Xbrane Biopharma



14.00 Göran Forsberg, CEO, Cantargia



14.15 Carlos de Sousa, CEO, Immunicum



14.30 Sten Sörensen, CEO, Cereno Scientific




14.45 Alex Haahr Gouliaev, CEO, Nuevolution



15.00 Christian Jørgensen, CEO, Biotec Pharmacon



15.15 Martin Waleij, CEO, BrainCool



15.30 Ulf Hannelius, President & CEO, Diamyd Medical



15.45 Petter Bäckgren, CEO, Bioservo Technologies



16.00 Thomas Areschoug, BD Manager, Xintela



16.15 Peter Buhl Jensen, CEO Oncology Venture



16.30 Thomas Feldthus, CFO, Saniona



16.45 Richard Godfrey, CEO, BerGenBio



Co-host partners:



**Preparing and executing
an IPO:**

Magnus Corfitzen, CEO,
Ascelia Pharma

**Pharma collaboration and
building partnerships:**

David Bejker, CEO,
Affibody

17.00

CLOSING PANEL: A LOOK TO THE FUTURE - PUBLIC MARKETS AND THE NORDICS IN A GLOBAL CONTEXT
Investors in public equities and leading sector analysts debate and discuss what they see as the biggest industry trends that will affect the biopharma industry and how the Nordics life sciences landscape fit in to this.

- Supporting the Nordic's ever-growing cohort of maturing life sciences companies and building on Europe's most robust retail investor base
- How long will the strong public listings environment continue in the Nordics and the USA?
- What could be the impact of geopolitical issues be on the wider biopharma sector, and what does it mean for publically listed Nordic life science companies?

John Rudy, Member, Mintz (moderator)
Torbjørn Bjerke, Founder & Portfolio Manager, Arctic Aurora LifeScience
Viktor Sundberg, Head of Healthcare Research, ABG Sundial Collier
Mattias Häggblom, Fund Manager, Swedbank Robur
Carsten Borring, Head of Listings & Capital Markets, Nasdaq Copenhagen

17.40

NETWORKING DRINKS

INVESTORS & PHARMA REGISTERED IN 2019



almi invest



BB Pureos Bioventures

BioSeed Capital

Bonit Capital



CASCARA ventures

CURAM CAPITAL



Forbion.
Impacting the future of medicine



HealthCap



Industriefonden



IPF Partners



KREOS CAPITAL



MAKI.VC



<norrskén>

novo holdings
Investors in life science



PONTIFAX



SOFINNOVA



startcodon

Sunstone
LIFE SCIENCE VENTURES



TEMASEK HOLDINGS

VEKSTFONDEN



Investor enquiries:

Brooke Roberts, VIP Networking Manager
brooke@lsxleaders.com or +44 (0) 203 637 5908

ATTENDEES IN 2018 INCLUDED....

CEO	2CureX	CEO	Medivir
Partner	ABG Sundial Colliar	Sr. Advisor - Life Sciences	Ministry of Foreign Affairs of Denmark
Partner	ABG Sundial Colliar	CEO	Modus Therapeutics
Partner	ABG Sundial Colliar	CMO	Modus Therapeutics
CEO	Active Biotech	Exec. Dir, Oncology S&E Lead	MSD
Chairman	AddBIO	Head Listings & Capital Markets	Nasdaq
CEO	Addlife	SVP, Head of European Listings	Nasdaq
Associate	Advent International	Managing Director	Nasdaq
CEO	Allbright Life Sciences	Managing Director	Nasdaq
CFO	Alligator Bioscience	Events and Listing Services	Nasdaq
CEO	Annexin Pharmaceuticals	Strategic Advisor	NDA Group
CFO	AntiBioTx	CEO	NDA Group
CEO	AntiBioTx	CEO	Neurovive
Founder and CIO	Arctic Asset Management	Corporate Analyst	Norrlandsfonden
Investment Director	Arix Bioscience	Vice President R&D Sourcing	Novo Nordisk
VP Pharmaceutical Sciences	AstraZeneca	Managing Partner	Novo Seeds
CEO	Athera Biotechnologies	CEO	Oblique Therapeutics
CFO	Bactiguard	CEO	Oncoinvent AS
CEO	Bactiguard	CEO	Oncology Venture
VD	BG & Co	COO	Oncology Venture
CEO & Editor	BioStock	CCO	Oncology Venture
CEO	Biotec Pharmacon	CEO	Orexo
CEO	Cantargia	CEO	OxThera
Managing Director	Cascara Ventures	Partner	PAI Partners
CEO	Cereno Scientific	Director, BD Europe	Patheon
CEO	Clinical Laserthermia Systems	CEO	Peptonic Medical
CEO	CytoVac	EU Head Global External R&D	Pfizer
CEO	Desentum	CEO	Promimic
CIO	Diklev Investments	Partner	PwC
CEO	Dilafor	Partner	PwC
CFO	Dilafor	Partner	PwC
CEO	Elypta	Group CEO & MD	ReAya Holding
Partner	EQT Partners	Partner	Ruffena Capital
CEO	EVM	Chairman	Saniona
CEO	Follicum	CEO	Saniona
CEO	Forward Pharma	Partner, Investment Advisor	Sarsia Seed
Partner	Gill Jennings & Every	CFO	Scandinavian Biopharma
Partner	Gill Jennings & Every	Managing Director	ScientificMed
Chief Innovation Officer	Global Core Medical	Investment Manager	Society
National Coordinator Life Sciences	Government Offices of Sweden	CEO	Society
Investment Advisor	GrayBella Capital	CEO	Sedana Medical
Vice President	H.C. Wainwright	CEO	Senzime
Managing Partner	Hadean Ventures	Partner	Serendipity Partners
Partner	HealthCap	Business Development	SmiLe Incubator
Partner	HealthCap	CEO	Snabbfoting Group
CEO	Herantis Pharma	CFO	SoundVision Enterprises
Senior Investment Manager	High-Tech Gründerfonds	Senior Partner	Sunstone Life Science Ventures
CEO	Immunicum	Portfolio Manager Global Healthcare	Swedbank Robur
CEO	Immunovia	Program Director	SwedenBIO
Investment Manager	Industrifonden	Managing Director	The Blueshirt Group
Head of Life Science	Industrifonden	Founder	The Unclouder
Investment Manager	Industrifonden	CEO	TikoMed
Investment Manager	Industrifonden	Investment Professional	Triton Investments Advisers
CEO	Initiator Pharma	Principal	TVM Capital
Managing Partner	Innovestor Ventures	Partner	Ventac Partners
Partner	IPF Partners	Partner	Vinge
Business Development Director	IQVIA	Partner	Vinge
CEO	Karolinska Development	Partner	Vinge
Life Sciences Securities	Kempen & Co	Partner	Vinge
Senior Associate	Kreos Capital	Partner	Vinge
General Partner	Kreos Capital	Partner	Vinge
Adviser	L1 Capital	CEO	VirTech Bio
Adviser	L1 Capital	Managing Partner	WildecO
CEO	Longboat Explorers	former CEO	Wilson Therapeutics
Co-CEO	LSX	CFO	Xbrane Biopharma
SVP	LSX	Partner, Investments	Xeraya Capital
Co-CEO	LSX	Financial Analyst - Life Sciences	Xplico
SVP	LSX	Partner	Xplico
Consultant	LucyJRobertshaw	CEO	Xspray Pharma
Associate	M Ventures	CFO	Zealand Pharma
EVP	Meabco		

| INVE\$TABLE

Inv€\$table Showcases exist for all stages of private and public companies to present news and deal flow and pitch an audience of active investors, and pharma. The showcases deliver succinct, hard hitting and insightful presentations allowing a qualified audience to uncover their next investment or partnership deal.

Presentations are recorded and a professional video is created for all showcasing companies and promoted for further outreach post-event to our global investor community.

| IPO BOOTCAMP

The IPO Bootcamp is a full-day forum in which a team of the region's foremost experts, advisers, bankers and consultants help 8 CEOs and CFOs navigate the how, what, where and when of a successful IPO.

In addition to 'no holds barred' discussions, it features tailored sessions, where each registering executive and company receive individual attention from the experts to talk through strategy, tactics, mechanics and ideas unique to them. The key USPs are a very high level and calibre of attendee and program, exclusivity, and a personalised approach. IPO candidates must pass a set of qualifying criteria to be considered for one of the 8 slots.

This full day bootcamp on day one for pre-qualified and pre-registered delegates only.

Co-hosted by:



JG:IR



VINGE

| PUBLIC CEO FORUM

| CEO DINNER

The LSX Public CEO Forums provides a unique, powerful and valuable space for the candid sharing of experience between the Nordic sector's senior executives so that they can leave with new ideas that will drive their publicly listed businesses and the region forward.

The CEO Dinner closes off the day of the CEO Forum and is an opportunity to continue discussions in a more informal setting over an exclusive dinner hosted by LSX. The dinner will be held at a restaurant in Stockholm away from the event venue. It is open to all CEO forum participants and included as part of the registration for the day, leading into the LSX Nordic Congress on the following day.

Co-hosted by:



VINGE

| PRIVATE CEO FORUM

The Private CEO Forum follows a similar format to the Public CEO Forum, but connects executives from the Nordic regions growth stage private life science companies for candid sharing of case studies on deals and experiences in growing and developing their businesses.

Co-hosted by:



STIFEL

| HEALTHTECH CEO FORUM

The HealthTech CEO Forum is designed to connect executives of the regions exciting new innovators in the digital health revolution, providing a unique format for the sharing of ideas and insights to grow and internationalise their healthtech businesses.

EVENT PARTNERS

HOST SPONSOR



GOLD SPONSORS



MEDIA PARTNERS



Industry Leading Events for the Life Science C-Suite



28-29 August 2019
Nasdaq Offices, Stockholm, Sweden
www.lsxleaders.com/nordic



7-8 October 2019
Convene Convention Center, Boston, USA
www.lsxleaders.com/usa



13-14 November 2019
The Crystal, Royal Victoria Dock, London, UK
www.lsxleaders.com/digihealth



19 November 2019
The Hilton Waldorf, London, UK
www.lsxleaders.com/investival



19 November 2019
The Honourable Artillery Company, London, UK
www.lsxleaders.com/lifestars



4-5 February 2020
etc. venues, 133 Houndsditch, London, UK
www.lsxleaders.com/london



21-22 April 2020
etc. venues, 133 Houndsditch, London, UK
www.longevityleaders.com

Contact us today to find out how to get involved in any or all of our events.

www.lsxleaders.com/events

2nd annual



**NORDIC
CONGRESS**

Sponsorship and
partnership opportunities:

Matt Pullan
SVP, BD & Partnerships
matt@lsxleaders.com
+44 (0) 203 637 5908

Speaker and agenda
opportunities:

Josh Dance
SVP
josh@lsxleaders.com
+44 (0) 203 637 5908

